Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Sep 19;10(1):96.
doi: 10.1186/s13195-018-0424-5.

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)

Stephen Salloway  1 , Lee A Honigberg  2 , William Cho  2 , Michael Ward  2 , Michel Friesenhahn  2 , Flavia Brunstein  2 , Angelica Quartino  2 , David Clayton  2 , Deborah Mortensen  2 , Tobias Bittner  3 , Carole Ho  2 , Christina Rabe  2 , Stephen P Schauer  2 , Kristin R Wildsmith  2 , Reina N Fuji  2 , Shehnaaz Suliman  2 , Eric M Reiman  4 , Kewei Chen  4 , Robert Paul  2
Affiliations
Clinical Trial

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)

Stephen Salloway et al. Alzheimers Res Ther. .

Abstract

Background: We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moderate Alzheimer's disease (AD).

Methods: This double-blind, placebo-controlled, randomized phase II study enrolled patients with mild-to-moderate AD and a Mini-Mental State Examination (MMSE) score of 18-26. In part 1 of the study, patients were 2:1 randomized to receive low-dose subcutaneous (SC) 300 mg crenezumab every 2 weeks (q2w) or placebo for 68 weeks; in part 2, patients were 2:1 randomized to receive high-dose intravenous (IV) 15 mg/kg crenezumab every 4 weeks (q4w) or placebo for 68 weeks. The primary endpoint was change in amyloid burden from baseline to week 69 assessed by florbetapir positron emission tomography (PET) in the modified intent-to-treat population. Secondary endpoints were change from baseline to week 69 in cerebrospinal fluid (CSF) biomarkers and fluorodeoxyglucose PET, and change from baseline to week 73 in 12-point Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog12) and Clinical Dementia Rating Sum of Boxes (CDR-SB). Safety was assessed in patients who received at least one dose of study treatment.

Results: From August 2011 to September 2012, 91 patients were enrolled and randomized (low-dose SC cohort: crenezumab (n = 26) or placebo (n = 13); high-dose IV cohort: crenezumab (n = 36) or placebo (n = 16)). The primary endpoint was not met using a prespecified cerebellar reference region to calculate standard uptake value ratios (SUVRs) from florbetapir PET. Exploratory analyses using subcortical white matter reference regions showed nonsignificant trends toward slower accumulation of plaque amyloid in the high-dose IV cohort. In both cohorts, a significant mean increase from baseline in CSF Aβ(1-42) levels versus placebo was observed. Nonsignificant trends toward ADAS-Cog12 and CDR-SB benefits were identified in a mild (MMSE 20-26) subset of the high-dose IV cohort. No amyloid-related imaging abnormalities due to edema/effusion were observed.

Conclusion: The primary endpoint was not met. Exploratory findings suggest potential Aβ target engagement with crenezumab and possible slower accumulation of plaque amyloid. Studies investigating the effects of higher doses of crenezumab on amyloid load and disease progression are ongoing.

Trial registration: ClinicalTrials.gov, NCT01397578 . Registered on 18 July 2011.

Keywords: Alzheimer’s disease; Antibodies; Biomarkers; Humanized; Monoclonal antibodies; Positron emission tomography.

PubMed Disclaimer

Conflict of interest statement

Authors’ information

MW, CH, SSu, and RP were employees of Genentech Inc., South San Francisco, CA, USA at the time of the study.

Ethics approval and consent to participate

This study was conducted at 21 sites in the US, one site in Spain, and one site in France. The study protocol was approved by the respective institutional review boards prior to participant recruitment and was conducted in accordance with US Food and Drug Administration regulations, International Council on Harmonization E6 Guideline for Good Clinical Practice, and applicable local, state, federal, and country laws. Written informed consent was obtained for all patients prior to performing study-related procedures in accordance with federal and institutional guidelines.

Consent for publication

Not applicable.

Competing interests

LAH, WC, MW, MF, FB, AQ, DC, DM, TB, CH, CR, SPS, KRW, SSu, RNF, and RP are current or former employees of Genentech (a member of the Roche Group), and own stock or stock options in F. Hoffmann-La Roche. SSa received grants and personal fees from Genentech during the conduct of the study, grants and personal fees from Eli Lilly, Biogen Idec, Merck, and Roche, and grants from Functional Neuromodulation, Avid, and Novartis. EMR received grants from Banner Alzheimer’s Institute during the conduct of the study, and is evaluating crenezumab in the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Trial. KC declares that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study disposition. One patient randomized to placebo received one dose of crenezumab treatment and was therefore included in the crenezumab arm of the safety population. IV intravenous, PET positron emission tomography, q2w every 2 weeks, q4w every 4 weeks, SC subcutaneous
Fig. 2
Fig. 2
Amyloid PET analysis. Analysis of the florbetapir change from baseline using three different methods for the calculation of SUVR: in the cerebellar gray MNI-CB (a,d), BAI-WM (b,e), and MNI-WM (c,f). The primary difference between these methods is the choice of reference region: cerebellar gray matter (SUVRMNI-CB) or subcortical white matter (SUVRMNI-WM and SUVRBAI-WM). The reference regions in both the low-dose SC (a–c) and high-dose IV (d–f) cohorts are shown. BAI Banner Alzheimer’s Institute, BL baseline, Cr crenezumab, Diff difference, IV intravenous, MNI molecular neuroimaging, Pl placebo, SC subcutaneous, SE standard error, SUVR standard uptake value ratio, WM white matter, CB cerebellar
Fig. 3
Fig. 3
CSF biomarkers. Analysis of the change in biomarker levels found in CSF (Aβ(1–42) (a,d), t-tau (b,e), and p-tau (c,f)) in both the low-dose SC (a–c) and high-dose IV (d–f) cohorts. CSF t-tau and p-tau was not analyzed for one patient at week 69. BL baseline, Cr crenezumab, CSF cerebrospinal fluid, Diff difference, IV intravenous, Pl placebo, p-tau phosphorylated tau, SC subcutaneous, SE standard error
Fig. 4
Fig. 4
Aβ(1–40) and Aβ(1–42) plasma concentrations. Mean (±SD) Aβ(1–40) and Aβ(1–42) plasma concentrations following low-dose SC or high-dose IV administration to patients with mild-to-moderate AD (weeks 1–69). Aβ beta-amyloid, AD Alzheimer’s Disease, IV intravenous, SC subcutaneous, SD standard deviation
Fig. 5
Fig. 5
ADAS-Cog12. Change from baseline of ADAS-Cog12 score in patients with mild-to-moderate AD (a,c) or mild AD (b,d) in both the low-dose SC (a,b) and the high-dose IV (c,d) cohort. % Red percentage reduction, AD Alzheimer’s disease, ADAS-Cog12 12-point Alzheimer’s Disease Assessment Scale cognitive subscale, BL baseline, Cr crenezumab, Diff difference, IV intravenous, MMSE Mini-Mental State Examination, Pl placebo, SC subcutaneous, SE standard error
See this image and copyright information in PMC

References

    1. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698–712. doi: 10.1038/nrd3505. - DOI - PubMed
    1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994. - DOI - PubMed
    1. Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–498. doi: 10.1016/0896-6273(91)90052-2. - DOI - PubMed
    1. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci. 2012;32:9677–9689. doi: 10.1523/JNEUROSCI.4742-11.2012. - DOI - PMC - PubMed
    1. Ultsch M, Li B, Maurer T, Mathieu M, Adolfsson O, Muhs A, et al. Structure of crenezumab complex with Aβ shows loss of β-hairpin. Sci Rep. 2016;6:39374. doi: 10.1038/srep39374. - DOI - PMC - PubMed

Publication types

Associated data